Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613391 | 0.97 | EGFR (0.74) | EGFRSRCERBB2KDRERBB4 | |
| SCHEMBL4034115 | 0.90 | EGFR (0.83) | EGFRSRCERBB2KDR | |
| SCHEMBL5660493 | 0.89 | EGFR (0.83) | EGFRSRCERBB2KDR | |
| SCHEMBL6402157 | 0.89 | EGFR (0.70) | EGFRSRCERBB2KDR | |
| SCHEMBL4032510 | 0.88 | EGFR (0.82) | EGFRSRCERBB2 | |
| SCHEMBL4034609 | 0.88 | EGFR (1.00) | EGFRSRCERBB2KDR | |
| SCHEMBL4205295 | 0.88 | EGFR (0.78) | EGFRSRCERBB2KDRERBB4 | |
| SCHEMBL4036906 | 0.87 | EGFR (0.85) | EGFRSRCERBB2KDR | |
| SCHEMBL5662811 | 0.87 | EGFR (0.81) | EGFRSRCERBB2 | |
| SCHEMBL5662719 | 0.87 | EGFR (0.79) | EGFRSRCERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885SRC 39/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.